Regeneron’s blockbuster eye drug Eylea saw U.S. sales fall to $1.43 billion in the first quarter of 2023, a 5% decrease from the previous quarter, and its second consecutive quarterly decline. Roche’s new-to-market Vabysmo — a rising competitor to Eylea — saw global sales jump 40% to $486 million in the same time period. Evaluate Pharma projects Vabysmo will bring in $1.5 billion in global sales by the end of 2023 and become the drugmaker’s fifth best-selling product in 2024. The FDA on May 9, meanwhile, accepted an application for Vabysmo to treat retinal vein occlusion, another Eylea stronghold. For the treatment of wet age-related macular degeneration, Vabysmo currently holds covered or better status for 80% of all insured lives under the medical benefit, to Eylea’s 97%.